INTRODUCTION

Type 2 diabetes is a chronic disease that has a major impact on public health and is a major cause of morbidity and mortality. However, the etiology of type 2 diabetes is not wholly understood, because type 2 diabetes is a complex disease that is influenced by many risk factors (1, 2). Fasting glucose (FG) level is an important type 2 diabetes related trait. A chronically elevated FG level reflects a damaged glucose metabolism and is a crucial risk marker for type 2 diabetes (3).

Furthermore, the heritability of FG level has been reported to be in 17%-51% in the general population (4). Therefore, knowledge of genetic susceptibility for FG level would improve our understanding of the risks of an impaired FG level and of type 2 diabetes.

Linkage and association analyses are the methods generally used to map genes that confer to susceptibility to complex diseases, such as, type 2 diabetes (5). Linkage analysis is performed on the joint distributions of trait and marker alleles in family members to determine whether a major gene associated with a familial trait is linked to a well-defined marker. Conversely, association analysis is useful for verifying susceptibility genes, in which the distributions of alleles at polymorphic markers are compared. Association studies are valuable for localizing regions of interest identified by linkage analysis. Recently, many researchers have performed linkage and association studies for...
complex disease using high throughput screening tools, and single-nucleotide polymorphism (SNP) arrays provide one of the most powerful high throughput screening approaches to genome-wide studies (6).

Adding twins can enrich a family study. Dizygotic (DZ) twins are valuable to gene mapping studies as ideal sib-pairs (7). Although monozygotic (MZ) twins do not contribute to gene mapping per se, the presence of them provides more precise discrimination between polygenic and shared environmental variance, which can potentially increase power of family-based regression methods (8).

Aiming at identifying novel or known genetic variations concerning FG level, we analyzed associations between genetic polymorphisms and FG level using a genome-wide SNP array chip in this study. In addition, we explored the trait of FG level in a healthy, family cohort containing MZ twins using a combined linkage/family-based association analysis approach.

MATERIALS AND METHODS

Population and data collection
In the present study, we used the Korean Healthy Twin study cohort data obtained from the Center for Genome Science at the Korean National Institute of Health. The aim of the Korean Healthy Twin cohort study was to explore genetic variation related to complex traits and to study the effects of environment on the etiologies of complex diseases, in adult same-sex twin pairs aged 30-yr or older and their first-degree family members regardless of family size. Participants were recruited by placing advertisements in daily newspaper and by using a poster campaign in about 300 hospitals and governmental agencies. The study design used in the Korean Healthy Twin study cohort has been previously described in detail (9). Of the 2,124 subjects in the cohort, we investigated 1,754 individuals, which included 432 families and 219 pairs of MZ twins (female and male pairs) after excluding individuals without an FG level. Participants in the Healthy Twin Study that signed a consent form before enrollment were interviewed by trained interviewers at each institution, and general epidemiological and clinical data were recorded. Subject weights and heights were also recorded, and blood samples were taken using standard protocols. Plasma glucose was assayed using a hexokinase enzymatic method.

Genotyping analysis
Genotyped data were obtained from the Center for Genome Science in the Korean Centers for Disease Control and Prevention. Sixteen short tandem repeat markers (15 autosomal short tandem repeat markers plus one sex-determining marker) were used to confirm sample identities for the twins (AmpFlSTR Identifier Kit; PerkinElmer, Norwalk, CT, USA). Only if at least 15 of the 16 markers corresponded in each twin pair, was the pair considered MZ (9). Microarray-based SNP genotyping was performed using the genome-wide human SNP array 6.0 chip (Affymetrix, Santa Clara, CA, USA). All genomic DNA samples were normalized to a concentration of 50 ng/μL. The Affymetrix standard protocol was followed. Genomic DNA was digested using restriction enzymes such as NspI and StyI and amplified by PCR. We labeled the amplified genomic DNA using Streptavidin, fragmented it to be 50-200 bp, and hybridized it in the chip. Scanning was performed using a high-resolution Affymetrix GeneChip scanner 3000 7G. Image files were used to transfer the data into GCOS 1.4 for subsequent processing using G-TYPE 4.0 software. Using V3 annotation for the genome-wide human SNP array 6.0 chip, a total of 906,600 SNPs and 946,000 copy number probes were genotyped per sample. Genotype calls were generated by a proprietary Birdseed 2.0 algorithm. Genotyped SNPs with a call rate of less than 95% were dropped. Monomorphic SNPs, SNPs with a minor allele frequency of < 0.01, or SNPs out of Hardy-Weinberg Equilibrium (P < 0.001) were filtered out. Finally, 520,484 SNPs were subjected to further analyses.

Statistical analysis
We examined the relationships between FG levels and covariates, such as, age, sex, and body mass index (BMI), using Spearman correlation coefficient test or Wilcoxon rank sum test (Mann-Whitney U test). Statistical analysis was performed using SAS version 9.1 (SAS Institute, Cary, NC, USA). Familial correlations of FG level between possible pairs in the pedigree and heritability of FG level were obtained using S.A.G.E. software, version 6.0.1 (http://darwin.cwru.edu/).

Combined genome-wide linkage analysis with peak wise association tests was performed to identify genetic markers of FG level. During the genome-wide linkage scan, multivariate regression-based quantitative trait loci (QTL) analysis of the number of alleles identical by descent (IBD) at a given marker was performed on the squared sum and squared difference of FG level after adjusting for confounders, such as, age, sex, and BMI (10). For adjusted FG level, we used regression residuals of log(FG_mic) on age, sex, and BMI in family members i (i = 1, 2, …) within the mth family. We considered S = [S_i = (X_i + X_j)^2] and D = [D_i = (X_i + X_j)^2] as predictor variables, and Π = [(π_i)] for the estimated proportion of alleles IBD_t_i (i.e.) as dependent variables in the multivariate regression model. MERLIN-REGRESS software (8) was used for extended regression based QTL analysis. For this analysis, we controlled overestimated genetic variance in the model caused by MZ twins sharing identical genotypes within pairs.

We next performed association studies for SNPs in linkage regions using a LOD score ≥ 1.3 in the genome-wide linkage analysis. We considered the T statistic of 2.45, which corresponds to a LOD score of 1.3, since 4.6 × LOD score is distributed as a 50-50 mixture of $\chi^2$ with 1 df and a point mass at 0 under the
null hypotheses of no linkage. We used two different association analysis approaches, that is, the family-based association test (FBAT) in all families and population-based tests of association in founders of each family, after adjusting for age, sex, and BMI to identify specific genetic loci associated with the risk of an increased FG level. Using FBAT, we merged each MZ twin’s pair as one subject by averaging traits, such as, BMI and FG level, of each MZ twin pair to adjust for possible overestimation of genetic variance in the model. FBAT under the additive model was used to allow both variations in a quantitative trait log(FG) and in covariates into a general score test of association in 1,535 subjects using FBAT software, version 2.0.3 (http://www.bios tat.harvard.edu/~fbat/).

Population-based association tests under various modes of inheritance, including additive, dominant and recessive models, and regression analyses of the log(FG) on interactive effects of significant SNPs were performed in 467 unrelated founders of each family using PLINK software, version 1.07 (http://pngu.mgh.harvard.edu/purcell/plink/). Of the additive, dominant, and recessive models for each SNP-trait association, we selected the best genetic model based on Akaikes information criterion (AIC). To combine two independent P values derived by FBAT and association analysis, we used Fisher’s method for combining P values (11).

Ethics statement

The study protocol of the healthy twin study was approved by the institutional review board of the Seoul National University (IRB No. 144-2011-07-11). Informed consent was submitted by all participants.

RESULTS

Distribution of subject characteristics

Table 1 shows the distribution of subject characteristics for all families and founders of each family. Founders tended to be older and had a higher FG level than all families. Comparisons of FG levels in unrelated population of founders showed they were different by sex (P = 0.028 by Wilcoxon’s rank sum test), and significantly correlated with age and BMI (r = 0.132, P = 0.004 for age and r = 0.156, P < 0.001 for BMI by Spearman correlation coefficient analysis). The proportions of study population with a history of type 2 diabetes were 5.3% for all families and 12.6% for founders.

Familial correlations of FG level between two random variables within nuclear family are shown in Table 2. Correlation estimate between MZ twins was moderately significant with r = 0.528 (SE = 0.049, P < 0.001), and was higher than that between pairs of full siblings (r = 0.257, SE = 0.034). No large differences were found between correlation estimates for all family members and families without one twin member in each pair of MZ twins. Heritability estimates for FG level were h² = 0.27 (SE = 0.07, P < 0.001) and adjusted h² = 0.47 (SE = 0.06, P < 0.001) (adjusting for age, sex and BMI). Without one member of twins in each pair of MZ twins, we obtained heritability estimates for FG level of h² = 0.31 (SE = 0.07, P < 0.001) and adjusted h² = 0.49 (SE = 0.06, P < 0.001) (adjusted for age, sex, and BMI).

Genome-wide linkage analysis

Initially, we performed an autosomal genome-wide linkage study for log(FG), after adjusting for age, sex, and BMI, using multi-

Table 1. Distribution of study population characteristics

| Parameters                  | All families | Founders only | P value |
|-----------------------------|--------------|---------------|---------|
| Age (yr)                    | 40 (35-55)   | 60 (60-65)    | 0.004†  |
| Sex                         |              |               |         |
| Male                        | 683 (38.9%)  | 94 (88-101)   |         |
| Female                      | 1071 (61.1%) | 89 (84-94)    |         |
| BMI (kg/m²)                 | 23.6 (21.4-25.8) | 24.7 (22.5-26.7) | < 0.001† |
| History of type 2 diabetes  |              |               |         |
| Yes                         | 1659 (94.8%) | 90 (84-95)    | < 0.001¹ |
| Total (No.)                 | 1,754        | 467           |         |

*No. (%) for categorical variables and Median (interquartile range) for continuous variables; †FG level: fasting glucose level (mg/dL); †P value as tested for Spearman correlation coefficient between the FG level and each variable; ¹P value as obtained by Wilcoxon rank sum test (Mann-Whitney U test) to test a difference of the FG level between two groups.

Table 2. Familial correlations of FG level between two random variables regarding each component of family members

| Relationships | All family members | Family members without one twin member in each MZ twins pair |
|---------------|--------------------|------------------------------------------------------------|
|               | No. of pairs       | Correlation ± SE | P value | No. of pairs | Correlation ± SE | P value |
| Parent-offspring | 1,327            | 0.193 ± 0.034   | < 0.001 | 1,068        | 0.200 ± 0.035    | < 0.001 |
| Full siblings  | 1,779             | 0.257 ± 0.034   | < 0.001 | 1,217        | 0.219 ± 0.039    | < 0.001 |
| MZ Twins       | 219               | 0.528 ± 0.049   | < 0.001 | 1,068        | 0.200 ± 0.035    | < 0.001 |
Fig. 1. Genome-wide linkage analysis with the FG level.
Table 3. The regions for evidence of linkage for the FG level

| Cytoband | Region (Mb) | Max LOD* | Position (bp) | Near SNP | Near gene* |
|----------|-------------|----------|---------------|----------|-----------|
| 2p23.3-2p31.1 | 151.8-172.1 | 2.33 | 172,072,250 | rs17287624 | C2orf37 |
| 3q13.11-3q13.13 | 105.2-110.6 | 2.05 | 105,215,684 | rs1900677 |          |
| 7p13 | 43.5 | 2.77 | 43,515,792 | rs11760314 | HECW1 |
| 15q26.1-15q26.3 | 91.1-99.9 | 2.26 | 98,347,739 | rs12916269 | ADAMTS17 |
| 16p12.1 | 22.8-26.5 | 2.39 | 22,838,204 | rs13239797 | USP31 |
| 16q12.1-16q13 | 48.8-54.9 | 2.08 | 48,775,110 | rs7192973 | PAPD5 |
| 20p13-20p12.2 | 0.0-9.2 | 2.77 | 2,970,618 | rs6138990 | FTYPR |

*The peak LOD score within the corresponding linkage region; †The nearest gene to the corresponding marker.

Table 4. Linkage regions which include known markers with significant evidence of association or linkage

| Cytoband | Region (Mb) | Max | Marker* | Position (bp) | Near gene | Trait* | Text† | Reference |
|----------|-------------|-----|---------|---------------|-----------|--------|-------|-----------|
| 2p23.3-2p31.1 | 151.8-172.1 | 2.33 | rs10181181 | 160,799,657 | T2D | GWAS | (33) |
|          |             |     | rs2925757  | 160,809,415 | T2D | GWAS | (33) |
|          |             |     | rs12692588 | 160,832,428 | T2D | GWAS | (33) |
|          |             |     | rs7572970  | 160,844,902 | RBMS1 | T2D | GWAS | (33) |
|          |             |     | rs1020731  | 160,852,301 | RBMS1 | T2D | GWAS | (33) |
|          |             |     | rs1020732  | 160,852,485 | RBMS1 | T2D | GWAS | (33) |
|          |             |     | rs12692592 | 160,871,627 | RBMS1 | T2D | GWAS | (33) |
|          |             |     | rs4077463  | 160,874,480 | RBMS1 | T2D | GWAS | (33) |
|          |             |     | rs7593737  | 160,879,700 | RBMS1 | T2D | GWAS | (33) |
|          |             |     | rs4589705  | 160,884,382 | RBMS1 | T2D | GWAS | (33) |
|          |             |     | rs1882347  | 164,116,560 | FG level | Linkage (LOD = 2.2) | (12) |
|          |             |     | D2S2330    | 166,406,837 | T2D | Linkage (LOD = 1.2) | (16) |
|          |             |     | D2S2345    | 168,428,635 | B3GALTL1 | T2D | Linkage (LOD = 3.0) | (5, 13) |
|          |             |     | rs650887   | 169,471,394 | GP1C2 | FG level | GWAS/Rep | (34-36) |
|          |             |     | rs630954   | 169,482,317 | GP1C2/ABCB11 | FG level | GWAS | (37) |
|          |             |     | rs757671   | 169,489,064 | ABCB11 | FG level | GWAS/Rep | (36) |
|          |             |     | rs483234   | 169,490,820 | ABCB11 | FG level | Rep.Assoc | (34) |
|          |             |     | rs3755157  | 169,500,417 | ABCB11 | FG level | Rep.Assoc | (34) |
|          |             |     | rs853778   | 169,510,498 | ABCB11 | FG level | GWAS | (35) |
|          |             |     | rs853778   | 169,519,470 | ABCB11 | FG level | Rep.Assoc | (34) |
| 15q26.1-15q26.3 | 91.1-99.9 | 2.26 | D1S1130    | 92,512,350 | Glucose 120 | Linkage (LOD = 1.3) | (14) |
|          |             |     | rs11073418 | 93,448,799 | T2D | GWAS | (38) |
|          |             |     | D1S1014    | 95,803,646 | Glucose 120 | Linkage (LOD = 1.3) | (14) |
| 16p12.1 | 22.8-26.5 | 2.18 | rs3760106  | 23,753,297 | PKCB1 | T2D | Rep.Assoc | (39) |
|          |             |     | rs2573390  | 23,754,255 | PKCB1 | T2D | Rep.Assoc | (39) |
|          |             |     | D1S6420    | 24,143,752 | PKCB1 | T2D | Rep.Assoc | (40) |
|          |             |     | D1S3605    | 25,468,276 | T2D | Linkage (NPL = 1.7) | (15) |
|          |             |     |          |            | T2D | Linkage (LOD = 1.4) | (16) |
| 16q12.1-16q13 | 48.8-54.9 | 2.08 | rs8050136  | 52,373,776 | FTO | T2D | GWAS | (6, 19, 20) |
|          |             |     | rs9039069  | 52,378,028 | T2D | GWAS | (19) |
| 20p13-20p12.2 | 0.0-9.2 | 2.78 | rs7361808  | 1,784,935 | SPINK1 | T2D | GWAS | (19) |
|          |             |     | D20S905    | 5,811,664 | T2D | Linkage (LOD = 3.1) | (17, 18) |
|          |             |     | rs958435   | 6,524,785 | T2D | Assoc | (20) |
|          |             |     | D20S892    | 6,698,245 | BMP2 | T2D | Assoc | (18) |
|          |             |     | D20S115    | 7,608,052 | T2D | Linkage (LOD = 1.7) | (17, 16) |
|          |             |     | rs1640410  | 7,685,540 | T2D | Assoc | (20) |

*The peak LOD score within the corresponding linkage region; †Trait tested for the corresponding study, T2D, Type 2 diabetes; FG level, fasting glucose level; glucose 120, glucose level obtained at 120 min interval; Statistical method to map genes. GWAS, genome-wide association study; Linkage, linkage analysis; Rep_assoc, replicated association study.

variate regression-based QTL analysis (10). We detected overall 7 peak regions in chromosomes 2, 3, 7, 15, 16, and 20 with significant evidence of linkage with FG level by genome-wide linkage analysis (Fig. 1). Top linkage peaks with LODs of > 2 in each region were located in chromosome 2q31.1 (172.1 Mb), 3q13.11 (105.2 Mb), 7p13 (43.5 Mb), 15q26.3 (98.3 Mb), 16p12.1 (22.8 Mb), 16q12.1 (48.8 Mb), and 20p13 (3.0 Mb), as shown in Table 3. Subsequently, we focused on SNPs in the 6 linkage regions of chromosomes 2q23.3-2q31.1, 3q13.11-3q13.13, 15q26.1-15q26.3, 16p12.1, 16q12.1-16q13, and 20p13-20p12.2 with relatively wide regions showing linkage (except for 7p13 in which only a small region showed linkage). Among these regions, we were able to find several well-known markers with significant evidence of linkage or association with FG level or risk of diabetes in the fol-
Association analyses for SNPs in the linkage peaks

We then performed two different association studies on SNP sites with an LOD score $\geq 1.3$ within the significant linkage regions described above. Using FBAT in all families, we identified 3 significant SNPs within 6 linkage regions associated with FG level after adjusting for age, sex, and BMI ($P < 0.001$, Table 5). We also performed population-based association analyses in founders only for each SNP with respect to FG level after adjusting for age, sex, and BMI for the various modes of inheritance. We confirmed 9 significant SNP sites using the best genetic model for each SNP within 6 linkage regions ($P < 0.001$, Table 5). By combining the two different $P$ values obtained by FBAT and association analysis, we were able to identify 4 significant SNPs, namely, rs16853036 located in the XIRP2 gene (xin actin-binding repeat containing 2 in chromosome 2q24.3), rs6497610 (in chromosome 16p12.1), rs6132978 in the VPS16 gene (vacuolar protein sorting 16 homolog in the chromosome 2q24.3), rs6516421, and rs6138953 located in the PTPRA gene (protein tyrosine phosphatase, receptor type, A in the chromosome 20p13) that were significantly associated with FG level with a combined $P < 0.001$ (Table 5). In particular, rs6138953 located in the PTPRA gene was found to be highly associated with FG level (combined $P = 1.8 \times 10^{-4}$) under the recessive model.

**DISCUSSION**

FG level is a typical complex trait related to type 2 diabetes that is affected by multiple genes. FG level does not follow any mode of Mendelian inheritance and its phenotype is widely variable. In this study, we used two ways to map genes that confer susceptibility to an elevated FG level, that is, genome-wide linkage and association analyses. Initially, we performed genome-wide linkage scan analysis using the Affymetrix SNP 6.0 chip with the objective of identifying those markers which are linked to major genes for FG level in all family members. We then used two different types of association analyses to identify susceptibility genes with the FG level and to localize linkage regions of concern in genes identified by genome-wide linkage scan analysis.

We found multiple regions with evidence of linkage that were associated with the risk of an elevated FG level in our healthy twin-family cohort. Based on our combined genome-wide linkage and association analyses, we were able to confirm several regions that have evidence of linkage with FG level and type 2 diabetes in different populations. In particular, regions of chromosomes 2q23.3-2q31.1, 15q26.1-15q26.3, 16p12.1, 16q12.1-16q13, and 20p13-20p12.2 (Table 4).

### Table 5. Significant SNPs* detected by FBAT or association analyses within the region for evidence of linkage

| Cytoband | Position(bp) | SNP rs* | Near gene | LOD* | MAF | Combined P value* (FBAT association analysis) | Best model# | Combined P value* (association analysis) |
|----------|--------------|---------|-----------|------|-----|---------------------------------------------|------------|------------------------------------------|
| 2q24.3   | 167,709,716  | rs16853036 | XIRP2     | 1.789 | 0.052 | 0.140 × 0.821 × 0.713 × 0.001 (rec) | rec        | < 0.001 (rec)                            |
| 2q31.1   | 171,404,718  | rs7561581  | GAD1      | 1.592 | 0.455 | 0.117 × 0.329 × 0.064 × 0.001 (dom) | dom        | 0.002                                   |
| 15q26.3  | 98,393,341   | rs2727184  | ADAMTS17  | 1.809 | 0.131 | 0.860 × 0.557 × 0.204 × 0.001 (rec) | rec        | < 0.001 (rec)                            |
| 16p12.1  | 22,846,113   | rs6497610  | TCTM2     | 2.242 | 0.386 | 0.251 × 0.862 × 0.071 × 0.001 (dom) | dom        | < 0.001 (dom)                            |
| 15q26.2  | 23,982,020   | rs11640219 | PRKCB1    | 1.757 | 0.047 | 0.057 × 0.012 × 0.057 × 0.001 (rec) | rec        | 0.005                                   |
| 16p12.1  | 23,994,362   | rs9923820  | PRKCB1    | 1.745 | 0.048 | 0.057 × 0.012 × 0.057 × 0.001 (rec) | rec        | 0.005                                   |
| 20p13    | 2,252,832    | rs2014045  | TGM3      | 1.956 | 0.138 | 0.434 × 0.617 × 0.239 × 0.001 (rec) | rec        | 0.002                                   |
| 20p12.3  | 2,532,331    | rs16897508 | TMC2      | 2.233 | 0.314 | 1.053 × 0.426 × 0.093 × 0.001 (rec) | rec        | 0.002                                   |
| 20p12.3  | 2,774,321    | rs6132978  | VPS16     | 2.644 | 0.078 | 2.235 × 0.001 (dom) | dom        | < 0.001 (dom)                            |
| 20p12.3  | 2,858,880    | rs6138853  | PTPRA     | 2.669 | 0.071 | 1.938 × 0.003 (dom) | dom        | < 0.001 (dom)                            |
| 20p12.3  | 8,868,528    | rs11906576 | TMC2      | 1.511 | 0.123 | 3.357 × 0.001 (rec) | rec        | 0.005                                   |
| 20p12.3  | 8,893,635    | rs6516421  | PTPRA     | 1.519 | 0.053 | 2.718 × 0.001 (rec) | rec        | 0.002                                   |

*Significant SNPs ($P < 0.001$) were selected from the FBAT or the association study among the SNPs with LOD $\geq 1.3$ within the regions with evidence of linkage; †The LOD score for the corresponding marker; ‡The general FBAT statistic; §$P$ values were calculated after adjusting for age, sex and BMI. Combined $P$ value for each SNP was derived using Fisher's method; †The best genetic model with the lowest AIC was selected among the dominant (dom), recessive (rec), and additive (add) models.

The findings of this study were mostly novel, however, of the following regions of chromosomes 2q23.3-2q31.1, 15q26.1-15q26.3, 16p12.1, 16q12.1-16q13, and 20p13-20p12.2 (Table 4).
identified genes (Table 5), PTPRA and PRKCB1 are likely to have direct/indirect impacts on insulin signaling and FG levels. The rs6138953 SNP in the intron region of PTPRA, located in 20p13, was found to be significantly associated with FG level under the recessive model in the present study. The protein encoded by the PTPRA gene is protein tyrosine phosphatase receptor type A (PTPRA), which is a member of the protein tyrosine phosphatase (PTP) family. PTPRA may play a role as a negative regulator of insulin signaling, and has been shown to dephosphorylate the insulin receptor, inhibit insulin-mediated effects, and modify insulin secretion in vitro (21). The expression of PTPRA is up-regulated in the skeletal muscles of obese humans (22), but unlike protein tyrosine phosphatase-1B (PTP1B) or leukocyte antigen related (LAR), there is insufficient evidence to prove its importance in insulin signaling. The present finding may support the suggestion that PTPRA participates in the pathogenesis of impaired glucose homeostasis in humans due to altered insulin signaling. In addition to its association with insulin signaling, PTPRA has been actively studied in relation to cancer. Protein tyrosine phosphorylation, which is controlled by protein tyrosine kinase (PTKs) and PTPs, plays an important role in various cellular events, such as, cell growth, differentiation, and oncogenesis (23), and the oncogenic function of various PTPs (PTPN11, PTPRH, PTPRF, and other) have been well demonstrated (24). However, concerning PTPRA, the function in human tumor biology has not been clearly verified, because in vitro (25) and clinical research (26) results in various cancers (colon, breast, gastric cancer, and other) are inconsistent. Therefore, further studies on the potential oncogenic role of PTPRA needed to be implemented.

The mutant types of rs11640219 and rs9923820, which are located in the intron region of the PRKCB1 gene (in 16p12.1), showed weak associations with FG level elevation according to the recessive model in the founder population in the present study. The protein encoded by PRKCB1 is protein kinase C (PKC) β (β1 and β2), which has been reported to be involved in glucose homeostasis and to play an important role in the pathogenesis of diabetic complications (27). Furthermore, the overexpressions of PKC/β1 and β2 was found to inhibit the tyrosine kinase activity of the insulin receptor in vitro (28), and PKC/β knockout mice showed mildly improved glucose homeostasis and increased glucose transport in muscle and adipose tissue (29). In another study, PKC/β2 overexpression was found to induce c-myc expression and to suppress insulin gene transcription in rat pancreatic islets (30). On the other hand, PKC/β2 was required to ensure adequate insulin-dependent glucose uptake in rat skeletal muscle (31). In another study by (32) a functional PKC β promoter polymorphism at position -546, which reduced promoter activity, was found to be associated with insulin resistance in human subjects. This study has several strengths. First, our data included various familial relationships in a Korean twin-family cohort, which enable us to identify evidence of genetic signals more accurately. Second, to the best of our knowledge, this is the first study to report linkages and associations of polymorphisms in chromosomes 16p12.1 and 20p13-20p12.2 with respect to FG level elevation. Concerning the 16p12.1 and 20p13-20p12.2 regions, little linkage and association analyses has been performed with respect to fasting glucose, insulin, and insulin resistance, because most research has been focused on type 2 diabetes and its complications. However, we found that the PTPRA and PRKCB1 genes among 11 selected genes (Table 5) are involved in glucose metabolism and insulin secretion directly or indirectly, and thus, may affect FG levels.

However, this study is limited by a lack of extensive fine-mapping and reliable replications of FG levels in individuals. Unclear biological understanding stayed behind for the other significantly detected polymorphisms, and thus, further studies are required on these polymorphisms. This study also has a limited power to identify well-known genetic variants involved in FG level, due to small sample size. Also, the absence of information on specific diabetic medications for the subjects who had diabetes is a limitation of our study.

In addition, meta-analyses of linkage regions and more extensive fine-mapping experiments that more broadly probe regions believed to contain additional markers associated with FG levels are needed in our future studies. Furthermore, replication studies are needed to explore the association between confirmed susceptibility loci and environmental factors of the trait.

Summarizing, we found multiple regions that showed evidence of linkage and an association with FG level in our Korean twin-family cohort. This study identifies that chromosomes 2q23.3-2q31.1, 15q26.1-15q26.3, 16p12.1, and 20p13-20p12.2 show evidence of linkage with FG level. In particular, SNP (rs-6138953) on PTPRA in the 20p13 region is associated with FG level, and the PRKCB1 gene (in 16p12.1) is possibly associated with FG level. These findings contribute to our understanding of the pathogenesis of type 2 diabetes in the Korean population. The combined approach of genome-wide linkage and family-based association analysis is useful to identify novel or known genetic regions concerning FG level in a family cohort study.

ACKNOWLEDGMENTS

The authors have no conflicts of interest to disclose.

REFERENCES

1. Ohlson LO, Larsson B, Björntorp P, Eriksson H, Svärdsudd K, Welin L, Tibblin G, Wilhelmsen L. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus: thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 1988; 31:
2. Manson JE, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, Krolewski AS, Rosner B, Hennekens CH, Speizer FE. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991; 338: 774-8.

3. Kim DJ, Cho NH, Noh JH, Kim HJ, Choi YH, Jung JH, Min YK, Lee MS, Lee MK, Kim KW. Fasting plasma glucose cutoff value for the prediction of future diabetes development: a study of Middle-Aged Koreans in a Health Promotion Center. J Korean Med Sci 2005; 20: 562-5.

4. Fradin D, Heath S, Lathrop M, Bougnères P. Quantitative trait loci for fasting glucose in young Europeans replicate previous findings for type 2 diabetes in 2q23-24 and other locations. Diabetes 2007; 56: 1742-5.

5. Huang QY, Cheng MR, Ji SL. Linkage and association studies of the susceptibility genes for type 2 diabetes. Yi Chuan Xue Bao 2006; 33: 573-89.

6. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes etiology. Nat Rev Genet 2007; 8: 657-62.

7. Martin N, Boomsma D, Machin G. A twin-pronged attack on complex traits. Nat Genet 1997; 17: 387-92.

8. Abecasis GR, Cherry SS, Cookson WO, Cardon LR. Merlin: rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 2002; 30: 97-101.

9. Sung J, Lee K, Song YM. Heritabilities of the metabolic syndrome phenotypes and related factors in Korean twins. J Clin Endocrinol Metab 2005; 94: 4946-52.

10. Sham PC, Purcell S, Cherny SS, Abecasis GR. Powerful regression-based quantitative-trait linkage analysis of general pedigrees. Am J Hum Genet 2002; 71: 238-53.

11. Elston RC. On fisher’s method of combining p-values. Biom J 1991; 33: 339-45.

12. Meigs JB, Manning AK, Fox CS, Florez JC, Liu C, Cupples LA, Dupuis J. heritability of fasting glucose level and confirmation of a locus on chromosome 1q21-q24. Diabetes 2003; 52: 550-7.

13. Martin N, Boomsma D, Machin G. A twin-pronged attack on complex traits. Nat Genet 1997; 17: 387-92.

14. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes etiology. Nat Rev Genet 2007; 8: 657-62.

15. Huang QY, Cheng MR, Ji SL. Linkage and association studies of the susceptibility genes for type 2 diabetes. Yi Chuan Xue Bao 2006; 33: 573-89.

16. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes etiology. Nat Rev Genet 2007; 8: 657-62.

17. Ghosh S, Watanabe RM, Hauser ER, Vallee TP, Magnuson VL, Erdos MR, Langelund CD, Balow J Jr, Ally DS, Kohtamäki K, et al. Type 2 diabetes: evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs. Proc Natl Acad Sci U S A 1999; 96: 2198-203.

18. Ghosh S, Watanabe RM, Hauser ER, Magnuson VL, Langelund CD, Balow Jr, ally MS, Mohlke KL, Silander K, Kohtamäki K, et al. The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) Study: I. an autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet 2000; 67: 1174-85.

19. Tsai FJ, Yang CF, Chen CC, Chuang LM, Lu CH, Chang CT, Wang TY, Chen RH, Shiu CF, Liu YM, et al. A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet 2010; 6: e1000847.

20. Hanson RL, Bogardus C, Duggan D, Koves S, Knowlton M, Infante AM, Marovich L, Benitez D, Baier LJ, Knowler WC. A search for variants associated with young-onset type 2 diabetes in American Indians in a 100K genotyping array. Diabetes 2007; 56: 3045-52.

21. Kapp K, Metzinger E, Kellerm M, Häring HU, Lammers R. The protein tyrosine phosphatase alpha modifies insulin secretion in INS-1E cells. Biochem Biophys Res Commun 2003; 311: 361-4.

22. Ahmad F, Azevedo JL, Corrigan R, Dohm GL, Goldstein B. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest 1997; 100: 449-58.

23. Hunter T. Protein kinases and phosphatases: the Yin and Yang of protein phosphorylation and signaling. Cell 1995; 80: 225-36.

24. Ostman A, Hellberg C, Böhm F. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006; 6: 307-20.

25. Zheng X, Resnick RI, Shalloway D. Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src. RNAi. Int J Cancer 2008; 122: 1999-2007.

26. Wu CW, Kao HL, Li AF, Chi CW, Lin WC. Protein tyrosine-phosphatase expression profiling in gastric cancer tissues. Cancer Let 2006; 242: 95-103.

27. Ishii H, Ilousse MK, Koya D, Takagi C, Xla P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WE, et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-31.

28. Bossenmaier B, Mostahl F, Mischak H, Ullrich A. Protein kinase C isoforms beta 1 and beta 2 inhibit the tyrosine kinase activity of protein kinase C beta 2 in c-myc induction by high glucose on glucose transport and glucose homeostasis. Endocrinology 1999; 140: 4470-7.

29. Kaneto H, Suh H, Kuma S, Sharma A, Bonner-Weir S, King GL, Weir GC. Involvement of protein kinase C beta 2 in e-nyc induction by high glucose in pancreatic beta-cells. J Biol Chem 2002; 277: 3680-5.

30. Kawano Y, Lincon J, Soler A, Ryder JW, Nolte LA, Zierath JR, Wallberg-Henriksson H. Changes in glucose transport and protein kinase C beta(2) in rat skeletal muscle induced by hyperglycaemia. Diabetologia 1999; 42: 1071-9.

31. Osterhov HF, Heuser S, Pfeiffer M, Tasic J, Kaiser S, Iksen F, Spranger J, Weickert MO, Möhlig M, Pfeiffer AE. Identification of a functional protein kinase C beta promoter polymorphism in humans related to insulin resistance. Mol Genet Metab 2006; 93: 210-5.

32. Wang Q, Lin JL, Reinkink B, Feng HZ, Chang FC, Lin CJ, Jin JP, Gustafson-Wagner EA, Scholz TD, Yang B, et al. Essential roles of an intercalated disc protein, mXinbeta, in postnatal heart growth and survival. Circ Res 422 http://jkms.org

http://dx.doi.org/10.3346/jkms.2013.28.3.415
34. Takeuchi F, Katsuya T, Chakravarthy S, Yamamoto K, Fujioka A, Serizawa M, Fujisawa T, Nakashima E, Ohnaka K, Ikegami H, et al. Common variants at the GCK, GCKR, G6PC2-ABCB11 and MTNR1B loci are associated with fasting glucose in two Asian populations. Diabetologia 2010; 53: 299-308.

35. Rasmussen-Torvik LJ, Alonso A, Li M, Kao W, Körtgen A, Yan Y, Couper D, Boerwinkle E, Bielinski SJ, Pankow JS. Impact of repeated measures and sample selection on genome-wide association studies of fasting glucose. Genet Epidemiol 2010; 34: 665-73.

36. Ramos E, Chen G, Shriner D, Doumatey A, Gerry NP, Herbert A, Huang H, Zhou J, Christman MF, Adeyemo A, et al. Replication of genome-wide association studies (GWAS) loci for fasting plasma glucose in African-Americans. Diabetologia 2011; 54: 783-8.

37. Chen WM, Erdos MR, Jackson AU, Saxena R, Sanna S, Silver KD, Timpson NJ, Hansen T, Orrù M, Grazia Piras M, et al. Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest 2008; 118: 2620-8.

38. Shu XO, Long J, Cai Q, Qi L, Xiang YB, Cho YS, Tai ES, Li X, Lin X, Chow WH, et al. Identification of new genetic risk variants for type 2 diabetes. PLoS Genet 2010; 6. pii: e1001127.

39. Ma RC, Tam CH, Wang Y, Luk AO, Hu C, Yang X, Lam V, Chan AW, Ho JS, Chow CC, et al. Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA 2010; 304: 881-9.

40. Ikeda Y, Suehiro T, Osaki F, Tsuzura S, Kunim Y, Hashimoto K. Polymorphisms in the 5'-upstream region of the PKCbeta gene in Japanese patients with Type 2 diabetes. Diabet Med 2004; 21: 1113-20.